Folia Biologica
Journal of Cellular and Molecular Biology, Charles University 

Crossref logo

Fol. Biol. 2007, 53, 129-133

https://doi.org/10.14712/fb2007053040129

HER-2 Tissue Expression Correlated with Serum Levels in Breast Cancer Patients

Olga Přibylová1, D. Springer2, I. Vítková3, T. Zima2, L. Petruželka1

1Department of Oncology, Charles University in Prague, 1st Faculty of Medicine and General Teaching Hospital, Prague, Czech Republic
2Institute of Clinical Biochemistry, Charles University in Prague, 1st Faculty of Medicine and General Teaching Hospital, Prague, Czech Republic
3Department of Clinical Pathology, Charles University in Prague, 1st Faculty of Medicine and General Teaching Hospital, Prague, Czech Republic

Received April 2007
Accepted May 2007

References

1. Baselga, J., Perez, E. A. (2006) Adjuvant trastuzumab: A milestone in the treatment of HER 2-positive early breast cancer. The Oncologist 11, 4-12. <https://doi.org/10.1634/theoncologist.11-90001-4>
2. Carney, W. P., Neumann, R., Lipton, A., Leitzel, K., Ali, S., Price, C. P. (2004) Monitoring the circulating levels of the HER2/neu oncoprotein in breast cancer. Clin. Breast Cancer 5, 105-116. <https://doi.org/10.3816/CBC.2004.n.014>
3. Cobleigh, M. A., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, V., Shak, S., Lieberman, G., Salamon, D. J. (1999) Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic cancer disease. J. Clin. Oncol. 17, 2639-2646. <https://doi.org/10.1200/JCO.1999.17.9.2639>
4. Drebin, J. A., Link, V. C., Stern, D.F. (1998) Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies. Cell 41, 697-706.
5. El-Sawy, W. H., Abou Taleb, F. M., Kader, M. A., Dorgham, Y. T., Radwan, D. A. (2002) Circulating HER2 extracellular domain and response to chemotherapy in metastatic breast cancer. J. Egypt. Natl. Cancer Inst. 14, 29-37.
6. Fornier, M. N., Seidman, A. D., Schwartz, M. K., Ghani, F., Thiel, R., Norton, L., Hudis, C. (2005) Serum HER 2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: association with HER 2 status by imunohistochemistry and fluorescence in situ hybridization and with response rate. Ann. Oncol. 16, 234-239. <https://doi.org/10.1093/annonc/mdi059>
7. Gebhardt, F., Zanker, K., Brandt, B. (1998) Differential expression of alternatively spliced c-erbB-2 mRNA in primary tumors, lymph node, metastases, and bone marrow micro metastases from breast cancer patients. Biochim. Biophys. Res. Commun. 247, 319-323. <https://doi.org/10.1006/bbrc.1998.8779>
8. Hait, W. N. (2001) The prognostic and predictive values of ECD-HER-2. Clin. Cancer Res. 7, 2601-2604.
9. Harries, M., Smith, I. (2002) The development and clinical use of trastuzumab (Herceptin). Endocr. Relat. Cancer 9, 75-85. <https://doi.org/10.1677/erc.0.0090075>
10. Hayes, D. F., Yamauchi, H., Broadwater, G., Cirrincione, C. T., Rodrigue, S. P., Berry, D. A., Younger, J., Panasci, L. L., Millard, F., Duggan, D. B., Norton, L., Henderson, I. C. (2001) Circulating HER-2/erbB-2/neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and leukemia group B study 8662. Clin. Cancer Res. 7, 2703-2711.
11. Hynes, N. E., Stern, D. F. (1994) The biology of erbB-2/neu/ HER-2 and its role in cancer. Biochim. Biophys. Acta 1198, 165-184.
12. Isola, J. J., Holli, K., Oska, H., Teramoto, Y., Kallioniemi, O. P. (1994) Elevated c-erbB2 oncoprotein levels in presurgery and follow-up serum sample defined in aggresive course in patients with breast cancer. Cancer 73, 652-658. <https://doi.org/10.1002/1097-0142(19940201)73:3<652::AID-CNCR2820730324>3.0.CO;2-4>
13. Kong, S. Y., Kang, J. H., Kwon, H. S., Chung, K. W., Kang, S. H., Lee, D. H., Ro, J., Lee, E. S.(2006) Serum HER-2 concentrations in patients with primary breast cancer. J. Clin. Pathol. 59, 373-376. <https://doi.org/10.1136/jcp.2005.029603>
14. Kraus, M. H., Issing, W., Miki, T., (1989) Isolation and characterization of ERBB3, a third member of the ERBB/ epidermal growth factor receptor family: evidence for overexpression in a subset of human mammary tumors. Proc. Natl. Acad. Sci. USA 86, 9193-9197. <https://doi.org/10.1073/pnas.86.23.9193>
15. Mazouni, C., Hall, A., Broglio, K., Andre, F., Esteva, F. J., Hortobagyi, G. N., Buzdar, A. U., Pusztai, L., Christofanilli, M. (2007) Kinetics of serum HER-2/neu changes in patients with HER-2 positive primary breast cancer after initiation of primary chemotherapy. Cancer 109, 496-501. <https://doi.org/10.1002/cncr.22418>
16. Olsen, D. A., Ostergaard, B., Bokmand, S., Wamberg, P. A., Jakobsen, E. H., Brandslund, I. (2007) HER-2 protein concentrations in breast cancer cells increace before immunohistochemical and fluorescence in situ hybridization analysis turn positive. Clin. Chem. Lab. Med. 45, 177-182. <https://doi.org/10.1515/CCLM.2007.034>
17. Perez, E. A. (2006) HER-2 as a prognostic, predictive, and therapeutic target in breast cancer. The Oncologist 11, suppl. 15-26. <https://doi.org/10.1634/theoncologist.11-10-1058>
18. Plowman, G. D., Culouscou, J. M., Whitney, G. S. (1993) Ligand-specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family. Proc. Natl. Acad. Sci. USA 90, 1746-1759. <https://doi.org/10.1073/pnas.90.5.1746>
19. Salvadori, B., Pinzani, P., Distante, V., Casella, D., Bianchi, S., Paglierani, M., Vezzosi, V., Neumann, R., Cataliotti, L., Pazzagli, M., Orlando, C. (2005) Comparison of pre and postsurgical concentrations of blood HER-2 mRNA and HER-2 ECD reflects HER-2 status in early breast cancer. Clin. Chem. 51, 254-256. <https://doi.org/10.1373/clinchem.2004.038844>
20. Schippinger, W., Regitnig, P., Bauernhofer, T., Ploner, F., Hofmann, G., Krippl, P., Wehrenschutz, M., Lax, S., Carney, W., Neumann, R., Werenecke, K. D., Samonigg, H. (2004) The course of serum HER-2/neu levels as an independent prognostic factor for survival in metastatic breast cancer. Oncol. Rep. 11, 1331-1336.
21. Slamon, D. J., Clark, G. M., Wong, S. G. (1997) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235, 177-182. <https://doi.org/10.1126/science.3798106>
22. Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., Yarden, Y., Sliwkowski, M. X. (2001) Untangling the ErbB signaling network. Nat. Rev. Mol. Cell. Biol. 2, 127-137.
23. Vogel, C., Cobleigh, M. A., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., Slamon, D. J., Murphy, M., Novotny, W. F., Burchmore, M., Shak, S., Stewart, S. J., Press, M. (2002) Eficacy and safety of trastuzumab as single agent first-line treatment of HER 2-overexpressing metastatic breast cancer. J. Clin. Oncol. 3, 719-726. <https://doi.org/10.1200/JCO.2002.20.3.719>
front cover

ISSN 0015-5500 (Print) ISSN 2533-7602 (Online)

Open access journal

Submissions

Archive